Return to Previous Page
Details
For a detailed description of Aβ 1-42, please see product H-1368.
For the preparation of Aβ for experimental use, Fezoui et al. (2000) found that solvation of synthetic peptide with sodium hydroxide (Aβ·NaOH) followed by lyophilization, produced stocks with superior solubility and fibrillogenesis characteristics. Solubilization of the pretreated material with neutral buffers resulted in a pH transition from ≈10.5 to neutral, avoiding the isoelectric point of Aβ (pI≈5.5), at which Aβ precipitation and aggregation propensity are maximal.
For the preparation of Aβ for experimental use, Fezoui et al. (2000) found that solvation of synthetic peptide with sodium hydroxide (Aβ·NaOH) followed by lyophilization, produced stocks with superior solubility and fibrillogenesis characteristics. Solubilization of the pretreated material with neutral buffers resulted in a pH transition from ≈10.5 to neutral, avoiding the isoelectric point of Aβ (pI≈5.5), at which Aβ precipitation and aggregation propensity are maximal.
Catalog Number
H-7404
One Letter Code
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
Synonyms
Aβ42 sodium salt
Molecular Formula
C₂₀₃H₃₁₁N₅₅O₆₀S
Relative Molecular Mass
4514.10
CAS Registry Number
[107761-42-2] net
Source
Synthetic
Storage Conditions
-20 ± 5 °C
Areas of Interest
Alzheimer's Disease
Antimicrobial & Antiviral Peptides
Antimicrobial & Antiviral Peptides
Links / Documents:
Related products
